A new promoter polymorphism in the gene of lipopolysaccharide receptor CD14 is associated with expired myocardial infarction in patients with low atherosclerotic risk profile

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 4, 1999, Pages 932-938

  Unkelbach, Katja ^a   Gardemann, Andreas ^a   Kostrzewa, Markus ^a   Philipp, Monika ^a   Tillmanns, Harald ^a   Haberbosch, Werner ^a,b  

^a KERCKHOFF HEART CENTER   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

CD14; Coronary disease; Genetics; Myocardial infarction; Risk factors

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CD14 ANTIGEN; CYTOKINE; GROWTH FACTOR; LIPOPOLYSACCHARIDE; PROCOAGULANT;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; ENDOTHELIUM CELL; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HUMAN; HUMAN CELL; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; RISK FACTOR; SINGLE STRAND CONFORMATION POLYMORPHISM;

EID: 0032949577     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.4.932     Document Type: Article

References (32)

1. Goyert SM, Ferrero E, Rettig WJ, Yenamandra AK, Obata F, Le Beau MM. The CD14 monocyte differentiation antigen maps to a region encoding growth factors and receptors. Science. 1988;239:497-500.
2. Simmons DL, Tan S, Tenen DG Nicholson-Weller A, Seed B. Monocyte antigen CD14 is a phospholipid anchored membrane protein. Blood. 1989;73:284-289.
3. Bazil V, Horejsi V, Baudys M, Kristofova H, Strominger JL, Kostka V, Hilgert I. Biochemical characterization of a soluble form of the 53 kDa monocyte surface antigen. Eur J Immunol. 1986;16:1583-1589.
4. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 1990;249:1431-1433.
5. Hailman E, Lichenstein HS, Würfel MM, Miller DS, Johnson DA, Kelley M, Busse LA, Zukowski MM, Wright SD. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J Exp Med. 1994;179:269-277.
6. Prey EA, Miller DS, Gullstein Jahr T, Sundan A, Bazil V, Espevik T, Finlay BB, Wright SD. Soluble CD 14 participates in the response of cells to lipopolysaccharide. J Exp Med. 1992;176:1665-1671.
7. Loppnow H, Stelter F, Schönbeck U, Schlüter C, Ernst M, Schütt C, Flad HD. Endotoxin activates human vascular smooth muscle cells despite lack of expression of CD14 mRNA or endogenous membrane CD14. Infect Immun. 1995;63:1020-1026.
8. Pugin J, Ulevitch RJ, Tobias PS. Activation of endothelial cells by endotoxin: direct versus indirect pathways and the role of CD14. Prog Clin Biol Res. 1995;392:369-373.
9. Schumann RR, Rietschel ET, Loppnow H. The role of CD14 and lipopolysaccharide-binding protein (LBP) in the activation of different cell types by endotoxin. Med Microbiol Immunol. 1994;183:279-297.
10. Montgomery KF, Osborn L, Hession C, Tizard R, Goff D, Vassallo C, Tarr PI, Bomsztyk K, Lobb R, Harlan JM, Pohlman TH. Activation of endothelial-leukocyte adhesion molecule 1 (ELAM-1) gene transcription. Proc Natl Acad Sci U S A. 1991;88:6523-6527.
11. Pober JS, Gimbrone MA Jr, Lapierre LA, Mendrick DL, Fiers W, Rothlein R, Springer TA. Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune Interferon. J Immunol. 1986;137:1893-1896.
12. Carlos TM, Schwanz BR, Kovach NL, Yee E, Rosso M, Osborn L, Chi-Rosso G, Newman B, Lobb R, Harlan JM. Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells. Blood. 1990;76:965-970.
13. Liao W. Endotoxin: possible roles in initiation and development of atherosclerosis. J Lab Clin Med. 1996;128:452-460.
14. Martinet Y, Bitterman PB, Mornex JF, Grotendorst GR, Martin GR, Crystal RG. Activated human monocytes express the c-sis protooncogene and release a mediator showing PDGF-like activity. Nature. 1986;319:158-160.
15. Rivers RPA, Hathaway WE, Weston WL. The endotoxin-induced coagulant activity of human monocytes. Br J Haematol. 1975;30: 311-316.
16. Colucci M, Balconi G, Lorenzet R, Pietra A, Locati D, Donati MB, Semeraro N. Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest. 1983;71:1893-1896.
17. Gensini GG. Coronary arteriography. In: Braunwald E, ed. Heart Disease. Philadelphia, Penn: WB Saunders, 1980:352-353.
18. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51:606. Letter.
19. Kawasaki ES. Sample preparation from blood, cells, and other fluids. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ, eds. PCR Protocols: A Guide to Methods and Applications. San Diego, Calif: Academic Press; 1990:146-152.
20. Ferrero E, Goyert SM. Nucleotide sequence of the gene encoding the monocyte differentiation antigen, CD14. Nucleic Acid Res. 1988;16:4173.
21. Zhang DE, Hetherington CJ, Tan S, Dziennis SE, Gonzalez DA, Chen HM, Tenen DG. Sp1 is a critical factor for the monocytic specific expression of human CD14. J Biol Chem. 1994;269:11425-11434.
22. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S, Tiret L, Amouyel P, Alhenc-Gelas F, Soubrier F. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992;359: 641-644.
23. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, Sorensen TI, Jensen G, Tybjaerg-Hansen A. ACE gene polymorphism: ischemic heart disease and longevity in 10,150 individuals. A case-referent and retrospective cohort study based on the Copenhagen City Heart Study. Circulation. 1997;95:2358-2367.
24. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med. 1996;334:1090-1094.
25. Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpainter K. P1A1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet. 1997;349: 385-388.
26. van der Bom JG, de Knijff P, Bots ML, Haverkate F, Hofman A, Kluft C, Grobbee DE. Polymorphism of the blood clot lysis enzyme tissue type plasminogen activator is associated with myocardial infarction. Circulation. 1995;92(suppl 2):1-30.
27. Ridker PM, Baker MT, Hennekens CH, Stampfer MJ, Vaughan DE. Alu-repeat polymorphism in the gene coding for tissue-type plasminogen activator (t-PA) and risks of myocardial infarction among middle-aged men. Arterioscler Thromb Vasc Biol. 1997;17:1687-1690.
28. Heinrich J, Schulte H, Schönfeld R, Köhler E, Assmann G. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost. 1995;73:374-379.
29. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332: 635-641.
30. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
31. Prescott MF, McBride CK, Court M. Development of intimal lesions after leukocyte migration into the vascular wall. Am J Pathol. 1989;135: 835-846.
32. Singh TM, Kadowaki MH, Glagov S, Zarins CK. Role of fibrinopeptide B in early atherosclerotic lesion formation. Am J Surg. 1990;160:156-159.